Actuate Therapeutics Inc

NASDAQ:ACTU

Biotechnology

Healthcare
$2.09 +2.96%

+$0.06 today

Market cap
$50.01M
Beta
0.53
P/E (TTM)
-2.3
EPS (TTM)
-$0.92
52W Low $1.58High $9.22

Volume 0.03M

Average 0.16M

ACTU Interest Income

Income earned on cash, deposits, and investments held by the company.

Actuate Therapeutics IncNASDAQ: ACTU

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income growth accelerates

Q1 FY2026 interest income of $85.27K rose 59.0% year over year, ahead of the +22.3% change in trailing-twelve-month interest income. Sequentially, it fell 38.9% from the prior quarter. Over 3 fiscal years it compounded at +120.0% a year.

Context

  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +59.0% holds above the trailing-twelve-month pace of +22.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$85.27K-38.9% QoQ
Last fiscal yearDec 2025
$287.71K+29.4% YoY
LTMMar 2026
$319.36K+22.3% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.0%——
1 year+29.4%——
3-year CAGR+120.0%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
287.71K USD
Year-over-year change
+29.4%
3-year CAGR
+120.0%

Interest Income vs competitors

How ACTU compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +22.3% is the 2nd highest of 8, against a peer median of -34.2%.
  • Over three fiscal years its annual growth of +120.0% compares with a peer median of +31.4%.
ACTU Competitors
Interest Income for ACTU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NKTXNkarta, Inc.LTM Mar 2026$13.96M USD-31.7%+40.5%—
VORVor Biopharma Inc.LTM Mar 2026$9M USD+153.2%+64.3%—
PEPGPepGen Inc.LTM Mar 2026$4.15M USD-36.5%+12.9%—
SPROSpero Therapeutics, Inc.LTM Mar 2026$1.98M USD-53.6%+31.4%3.6%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$1.93M USD-34.2%-10.0%168.6%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.48M CHF-47.8%+8.4%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$723K USD-13.6%+128.8%—
ACTUActuate Therapeutics IncLTM Mar 2026$319.36K USD+22.3%+120.0%—
ALECAlector, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding ACTU) —-34.2%+31.4%3.6%

Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development16.39M21.71M18.68M10.29M
Selling, General & Admin3.82M3.27M6.48M12.2M
Operating Expenses20.21M24.97M25.16M22.5M
Depreciation & Amortization63.61K272.85K2.14M0
EBITDA(20.08M)(24.43M)(25.16M)(22.21M)
EBITDA Margin————
Operating Income(20.21M)(24.97M)(25.16M)(22.5M)
Operating Margin————
Interest Income27.03K352.67K222.29K287.71K
Interest Expense16.2K43.64K(18.72K)20.25K
Other Income / Expenses47.41K229.21K(2.12M)267.46K
Income Before Tax(20.16M)(24.74M)(27.28M)(22.23M)
Pre-Tax Margin————
Income Tax Expense008000
Net Income(20.16M)(24.74M)(27.29M)(22.23M)
Net Margin————
EPS (Basic)(1.34)(1.65)(3.26)(1.06)
EPS (Diluted)(1.34)(1.65)(3.26)(1.06)
Weighted Avg Shares15.03M15.03M19.51M21.02M
Weighted Avg Shares (Diluted)15.03M15.03M19.51M21.02M

Actuate Therapeutics Inc

NASDAQ:ACTU

Intrinsic Alpha fair value

Locked

Current Price

$2.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.